Quadrivalent Influenza Vaccine

Brand names: AFLURIA Quadrivalent, Fluarix Quadrivalent, FluLaval Quadrivalent, Flucelvax Quadrivalent and Fluzone Quadrivalent, FluMist Quadrivalent

What is quadrivalent flu vaccine?

A quadrivalent influenza (flu) vaccine is designed to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses.

Learn more about the vaccine composition for the current flu season vaccines.

Why was quadrivalent flu vaccine developed?

For many years, flu vaccines were designed to protect against three different flu viruses: an influenza A(H1N1) virus, an influenza A(H3N2) virus and one influenza B virus, even though there are two different lineages of B viruses that circulate during most seasons. Adding a B virus from the second lineage was done to give broader protection against circulating flu viruses.

Who can get quadrivalent flu vaccine?

All flu vaccines in the United States are quadrivalent. Different vaccines are approved for different age groups. Information on approved flu vaccines for the 2021-2022 flu season, and age indications for each vaccine are available in CDC’s Table: U.S. Influenza Vaccine Products for the 2021-2022 Season.

Who shouldn’t get quadrivalent flu vaccine?

Different influenza (flu) vaccines are approved for use in people in different age groups. In addition, some vaccines are not recommended for certain groups of people. Factors that can determine a person’s suitability for vaccination, or vaccination with a particular vaccine, include a person’s age, health (current and past) and any allergies to flu vaccine or its components. For more information, visit Who Should and Who Should NOT get a Flu Vaccine.

Are any of the available flu vaccines recommended over the others?

Yes, for some people. For the 2022-2023 flu season, there are three flu vaccines that are preferentially recommended for people 65 years and older. These are Fluzone High-Dose Quadrivalent vaccine, Flublok Quadrivalent recombinant flu vaccine or Fluad Quadrivalent adjuvanted flu vaccine. On June 22, 2022, CDC’s Advisory Committee on Immunization Practices (ACIP) voted unanimously to preferentially recommend these vaccines over standard-dose unadjuvanted flu vaccines. This recommendation was based on a review of available studies which suggests that, in this age group, these vaccines are potentially more effective than standard dose unadjuvanted flu vaccines. There is no preferential recommendation for people younger than 65 years.

What if a preferentially recommended flu vaccine is not available?

If one of the three preferentially recommended flu vaccines for people 65 and older is not available at the time of administration, people in this age group should get an age-appropriate standard-dose flu vaccine instead.

How much quadrivalent flu vaccine will be available for the United States during the 2022-2023 flu season?

All flu vaccine for the 2022-2023 season is quadrivalent. More information about flu vaccine supply is available.

Are quadrivalent flu vaccines safe?

Yes. Flu vaccines that protect against four flu viruses have a safety profile similar to seasonal flu vaccines made to protect against three viruses, with similar—mostly mild—side effects. Like all seasonal flu vaccines, vaccines that protect against four flu viruses are monitored annually for their safety and effectiveness.

For information about flu vaccine side effects, see “Can the flu vaccine give me the flu?”

Special Consideration Regarding Egg Allergy

People with egg allergies can receive any licensed, recommended age-appropriate influenza vaccine (IIV4, RIV4, or LAIV4) that is otherwise appropriate. People who have a history of severe egg allergy (those who have had any symptom other than hives after exposure to egg) should be vaccinated in a medical setting, supervised by a health care provider who is able to recognize and manage severe allergic reactions. Two completely egg-free (ovalbumin-free) flu vaccine options are available: quadrivalent recombinant vaccine and quadrivalent cell-based vaccine.